Procalcitonin Test Research Articles

Point-of-care procalcitonin trends in suspected neonatal late-onset infection: a prospective observational study.

Procalcitonin-guided antimicrobial decision-making has been shown to be safe in adult intensive care settings. Most antimicrobial exposure in neonatal units is in culture-negative conditions. We hypothesise that Procalcitonin aids antimicrobial stewardship efforts in suspected Late-Onset Neonatal Sepsis. Neonates were enrolled if they were aged over 72 h and were placed on antibiotics for a suspected infection. Procalcitonin levels were taken at set timepoints for the duration of antimicrobial exposure. Three subgroups were created: non-infectious episodes, blood culture-negative infectious episodes, and bloodstream infections. Eighty-five suspected infectious episodes were recruited across two tertiary neonatal and paediatric intensive care units. There was a significant difference between the median PCT in bloodstream infections (BSI) compared to non-infectious episodes (2.13 versus 0.26 µg/L, p < 0.001). A cut-off of 0.5 µg/L had sensitivity 92.9% and specificity 68% for bloodstream infections at 24 h. The difference between median PCT values at 24 h was significant (0.27 vs 7.08; p < 0.001) for feed intolerance vs. NEC Grade IIIa-IIIb subgroups. Procalcitonin levels taken 24 h following evaluation for late-onset neonatal infection are useful in out ruling BSI or severe Necrotising Enterocolitis. Up to 30% of antimicrobial exposure could be avoided with the use of Procalcitonin levels in low-risk neonates. This study demonstrates the utility of serial Procalcitonin measurements in antimicrobial stewardship efforts in the Neonatal Unit. Procalcitonin can be used to aid in antimicrobial decision making in suspected Late-Onset neonatal infection. Procalcitonin testing at twenty-four hours in episodes of Gastrointestinal deterioration can out rule Bells Grade III Necrotising Enterocolitis.

ANTIBACTERIAL THERAPY IN SEPSIS PATIENTS

Today, sepsis, the cause of which is purulent-inflammatory processes of soft tissues, accounts for more than 45% of cases. In most multidisciplinary hospitals, the frequency of gram-positive and gram-negative sepsis is approximately the same. Antibacterial therapy (ABT) is the most important component of the complex therapy of sepsis, and early adequate empiric ABT leads to a decrease in mortality and the frequency of complications. ABT of sepsis at the beginning of treatment, in most cases, is empirical in nature, but it should be remembered that taking the material for microbiological research must be done before the start of antibacterial therapy! According to the principles adopted in the guideline "Sepsis - 3", the use of antibiotics for the treatment of sepsis is a necessary component, the effectiveness of which cannot be doubted. It should be remembered that a delay in the appointment of an antibacterial drug to patients with sepsis and septic shock for 1 hour leads to an increase in the risk of death of the patient by 7,6%. Empiric ABT should be initiated with a broad-spectrum regimen of one or more antibiotics in patients with sepsis or septic shock to cover all possible pathogens (including bacterial, possibly fungal, or viral). Empiric ABT should be narrowed after identification of the pathogen and determination of its sensitivity and/or when adequate clinical improvement is registered. There are no indications for long-term systemic antibacterial prophylaxis in patients with severe forms of inflammatory conditions of non-infectious origin (for example, severe pancreatitis, burns). Measurement of procalcitonin levels can be used to shorten the duration of antibacterial therapy in patients with sepsis. Rapid interpretation of the severity of the infectious process can be performed using ACCP/SCCM sepsis diagnostic criteria, organ dysfunction criteria (gSOFA, SOFA, MODS) or rapid procalcitonin test. Microbiological diagnosis of sepsis is the main factor in prescribing adequate ABT regimens. In the case when the same microorganism is released from the probable source of infection and from the peripheral blood, its etiological role in the development of sepsis should be considered as evidential. The standard for testing blood for sterility is the collection of material from two peripheral veins with an interval of up to 30 minutes, while blood from each vein must be collected in two vials. It is not permissible to take blood from the catheter! Building an ABT algorithm taking into account the etiology and characteristics of resistance of microorganisms to antibacterial drugs is the most optimal approach. Тoday, the optimal regimen of empiric ABT of sepsis with PON is carbapenems - as drugs that have the widest spectrum of action and to which the lowest level of resistance is observed among intra-hospital strains of gram(-) bacteria. In some cases, an alternative to carbapenems is cefepime, ceftaroline, protected by antipseudomonas β-lactams (cefaperazone/sulbactam, piperacillin/tazobactam) and "respiratory" fluoroquinolones. In cases of ineffectiveness of the indicated regimens of ABT, the feasibility of additional appointment of glycopeptides (vancomycin, teicoplanin or linezolid), as well as systemic antimycotics (fluconazole) should be evaluated. The latter should also be prescribed after 7-10 days after the start of ABT in a prophylactic dose of 150 mg per week.

A-246 Can CRP be used to rule in or rule out elevated procalcitonin concentrations in the emergency department?

Abstract Background C-reactive Protein (CRP) and procalcitonin (PCT) are commonly used sepsis biomarkers but have very different properties. PCT rises earlier, has a shorter half-life and is more specific for sepsis than CRP. It is however significantly more expensive. This study examined whether CRP measurement can be used to screen for the need for PCT measurement in emergency department patients. Methods This was a retrospective study of anonymized records of paired CRP and PCT requests from the emergency department during 2023. All testing was performed using Beckman Coulter AU 5800 (CRP) and Roche e601 (PCT). PCT results were interpreted using the 2023 AACC guidelines on PCT use (PCT&amp;lt;0.1 ug/L: strongly discourage antibiotic use; PCT 0.1-0.25: discourage antibiotic use; PCT 0.26-0.5: encourage antibiotic use; PCT&amp;gt;0.5: strongly encourage antibiotic use) and the ability of CRP to predict PCT exceeding the various cutoffs was calculated using Microsoft Excel and Analyse-It statistical add-on. Results There were 1645 paired results available. The CRP concentrations at 95% and 99% sensitivity and specificity levels for the various PCT cutoffs are shown in the table, together with the projected reductions in PCT testing volumes if PCT testing is restricted to samples with CRP within the ranges defined by the 95% or 99% sensitivity/specificity values. For example, from the table, for PCT&amp;gt;0.1 ug/L cutoff at 95% confidence, subsequent PCT measurement on the sample is only performed if CRP is between 3.4 and 90.5 mg/L. Conclusions Limiting PCT measurements to samples with CRP concentrations inside ranges based on the PCT cutoff of interest and the appropriate confidence level (95% or 99%) can potentially reduce PCT testing by 20-40% in emergency department patients. For laboratories which perform CRP and PCT analysis sequentially on different platforms, this approach allows significant reductions in PCT test volumes while ensuring testing is performed in equivocal cases.

The Clinical Lens: It is time to start using the right test for febrile young infants

Abstract Fever among infants in the first months of life is a common clinical conundrum facing all clinicians who treat children. Most well-appearing febrile young infants have viral illnesses. However, it is critical to identify those at risk of invasive bacterial infections, specifically bacteremia and bacterial meningitis. Clinicians must balance the risks of missing these infections against the harms of over-investigation. Procalcitonin testing is currently the best diagnostic test available to help guide management, and the Canadian Paediatric Society Position Statement on the management of febrile young infants recommends procalcitonin-based risk stratification. However, in many clinical settings, procalcitonin is either unavailable or has a turnaround time that is too long to aid decision-making. Clinicians who care for febrile young infants must have rapid access to procalcitonin results to provide best-evidence, guideline-adherent care. The wider availability of this test is essential to reduce unnecessary invasive testing, hospitalizations, and antibiotic exposure and could reduce system-wide resource utilization.

Hospital Variations and Temporal Trends in Procalcitonin Use for Patients With Bronchiolitis.

The financial burden of bronchiolitis-related hospitalizations in the United States surpasses $700 million annually. Procalcitonin (PCT) has garnered recent interest in pediatrics and has demonstrated the potential to decrease antibiotic usage in other illnesses. This study assessed PCT utilization trends in bronchiolitis, hypothesizing an annual increase in PCT testing. We conducted a multicenter, retrospective cross-sectional study utilizing the Pediatric Health Information Systems database. Infants aged 2 to 23 months presenting with bronchiolitis from January 1, 2016, to December 31, 2022, were included. Encounters with and without PCT testing were compared using χ2 testing and Wilcoxon rank-sum testing as appropriate. Temporal trends in PCT testing and correlations with hospital-level proportions of PCT use, antibiotic administration, and admission proportion were assessed using Spearman's ρ. There were 366 643 bronchiolitis encounters among 307 949 distinct patients across 38 hospitals during the study period. Of those, 1.5% (5517 of 366 643) had PCT testing performed. PCT usage increased more than 14-fold between 2016 and 2022 (0.2% in 2016 vs 2.8% in 2022, ρ > 0.99, P < .001). PCT use ranged from 0.01% to 8.29% across hospitals. The hospital-level proportion of PCT testing was not associated with admissions (ρ = 0.13, P = .42) or antibiotic use (ρ = 0.31, P = .06). PCT testing in patients with bronchiolitis increased 14-fold between 2016 and 2022 and was not associated with decreased antimicrobial prescriptions. Further studies are needed to determine the diagnostic yield of PCT in bronchiolitis.

A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19.

Procalcitonin (PCT) is a blood marker used to help diagnose bacterial infections and guide antibiotic treatment. PCT testing was widely used/adopted during the COVID-19 pandemic in the UK. Primary: to measure the difference in length of early (during first 7 days) antibiotic prescribing between patients with COVID-19 who did/did not have baseline PCT testing during the first wave of the pandemic. Secondary: to measure differences in length of hospital/ICU stay, mortality, total days of antibiotic prescribing and resistant bacterial infections between these groups. Multi-centre, retrospective, observational, cohort study using patient-level clinical data from acute hospital Trusts/Health Boards in England/Wales. Inclusion: patients ≥16 years, admitted to participating Trusts/Health Boards and with a confirmed positive COVID-19 test between 1 February 2020 and 30 June 2020. Data from 5960 patients were analysed: 1548 (26.0%) had a baseline PCT test and 4412 (74.0%) did not. Using propensity-score matching, baseline PCT testing was associated with an average reduction in early antibiotic prescribing of 0.43 days [95% confidence interval (CI): 0.22-0.64 days, P < 0.001) and of 0.72 days (95% CI: 0.06-1.38 days, P = 0.03] in total antibiotic prescribing. Baseline PCT testing was not associated with increased mortality or hospital/ICU length of stay or with the rate of antimicrobial-resistant secondary bacterial infections. Baseline PCT testing appears to have been an effective antimicrobial stewardship tool early in the pandemic: it reduced antibiotic prescribing without evidence of harm. Our study highlights the need for embedded, rapid evaluations of infection diagnostics in the National Health Service so that even in challenging circumstances, introduction into clinical practice is supported by evidence for clinical utility. ISRCTN66682918.

Combining PCT with CRP is better than separate testing for patients with bacteriuria in the intensive care unit: a retrospective study

BackgroundPrevious studies on PCT for urinary tract infections (UTI) have focused primarily on minors. This study investigated the predictive value of the neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP) level and procalcitonin (PCT) level in adult patients with bacteriuria in IUC.MethodsThis case‒control study included 85 patients with bacteriuria (PB) in the ICU from March 2021 to Jan 2024 based on positive urine culture results and a control group (n = 136) from Jan 2024 to March 2024. Patient data were collected using a hospital information management system. ROC curves of the NLR, CRP and PCT were use to predict the PB.ResultsThe AUCs of the NLR, CRP and PCT for the prediction of PB in ICU were 0.711 (95% CI 0.644–0.772), 0.855 (95% CI 0.800–0.900), and 0.884 (95% CI 0.832–0.924), respectively; the optimal thresholds were 8.02, 18.52 mg/L, and 0.215 ng/mL, respectively; the sensitivities were 69.0 (95% CI 56.9–79.5), 90.1 (95% CI 80.7–95.9), and 83.1 (95% CI 72.3–91.0), respectively; and the specificities were 67.6 (95% CI 59.1–75.4), 68.4 (95% CI 59.9–76.1), and 80.9 (95% CI 73.3–87.1), respectively. The negative predictive value (NPV) of CRP is greater than that of PCT. In bacteriuria caused by Candida infections, CRP and PCT have higher sensitivity and NPV.ConclusionsCombined CRP and PCT testing is more helpful for diagnosing bacteriuria. CRP and PCT have higher sensitivity and NPV in diagnosing bacteriuria caused by Candida infection.

Paper-Based procalcitonin and Interleukin-6 test strip with Spectrum-Based optical reader for enterovirus severity differentiation in children

Infectious diseases significantly impact global health, necessitating prompt diagnosis to mitigate life-threatening sepsis risk. Identifying patients at risk of severe neurological complications from enterovirus infections is challenging due to nonspecific initial presentations. Point-of-care testing (POCT) has emerged as a transformative tool, with low-cost lateral-flow colorimetric assays showing promise in deployable POCT devices. We developed a PCT/IL-6 rapid diagnostic system integrating lateral flow assay (LFA) test strips and a portable optical spectrum reader, allowing simultaneous semi-quantitative measurement of serum PCT and IL-6 within 30 min at the point of care. The system demonstrated a strong correlation with traditional ELISA and effectively differentiated severe pediatric enterovirus cases using serum samples. IL-6 showed superior discriminatory ability over PCT in identifying patients with severe neurological complications. This novel diagnostic platform holds great potential for early sepsis recognition and infectious disease management, especially in resource-limited settings.

Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer.

Medullary thyroid cancer (MTC) shows a relatively poor prognosis among thyroid cancers. Though calcitonin has been used as a diagnostic marker for MTC, it has disadvantages including poor sample stability and discrepancies among results by assay. This study aimed to compare the usefulness of preoperative calcitonin and procalcitonin (PCT) in the diagnosis of MTC. Serum calcitonin and PCT levels were measured before thyroidectomy from MTC (n = 23) and other types of thyroid cancers in patients (n = 1308). Diagnostic performances of calcitonin and PCT for discerning MTC were estimated. In a multivariate analysis, preoperative calcitonin level was independently associated with the diagnosis of MTC, whereas PCT was not. Calcitonin and PCT, respectively, exhibited area under the curve values of 0.997 and 0.979 for the diagnosis of MTC, without significant differences. For calcitonin, the sensitivity, specificity, and positive and negative predictive values were 0.957, 0.992, 0.688, and 0.999, respectively, at a cut-off of 7.2 pg/mL. The corresponding values for PCT were 0.913, 0.995, 0.778, and 0.998 at a cut-off of 0.19 ng/mL. Preoperative calcitonin and PCT showed similar diagnostic utility for MTC. Depending on the patient's clinical status and laboratory environment, these tests can be used as complementary methods for detecting MTC.

Prevalence and predictors of antibiotic prescription among patients hospitalized with viral lower respiratory tract infections in Southern Province, Sri Lanka.

Antimicrobial overprescription is common for lower respiratory tract infections (LRTI), as viral and bacterial infections generally present with similar clinical features. Overprescription is associated with downstream antimicrobial resistance. This study aims to identify the prevalence and predictors of antibiotic prescription among patients hospitalized with viral LRTI. A prospective cohort study was conducted among patients aged ≥1 year hospitalized with viral LRTI in a tertiary care hospital in Southern Province, Sri Lanka from 2018-2021. Demographic, clinical, and laboratory data were recorded. Nasopharyngeal and blood samples were collected for multiplex polymerase chain reaction testing for 21 respiratory pathogens and procalcitonin (PCT) detection, respectively. Demographic and clinical features associated with antibiotic prescription were identified using Chi Square and t-tests; significant variables (p<0.05) were further included in multivariable logistic regression models. The potential impact of biomarker testing on antibiotic prescription was simulated using standard c-reactive protein (CRP) and PCT cut-offs. Of 1217 patients enrolled, 438 (36.0%) had ≥1 respiratory virus detected, with 48.4% of these patients being male and 30.8% children. Influenza A (39.3%) and human rhinovirus/ enterovirus (28.3%) were most commonly detected. A total of 114 (84.4%) children and 266 (87.8%) adults with respiratory viruses were treated with antibiotics. Among children, neutrophil percentage (median 63.6% vs 47.6%, p = 0.04) was positively associated with antibiotic prescription. Among adults, headache (60.6% vs 35.1%, p = 0.003), crepitations/crackles (55.3% vs 21.6%, p<0.001), rhonchi/wheezing (42.9% vs 18.9%, p = 0.005), and chest x-ray opacities (27.4% vs 8.1%, p = 0.01) were associated with antibiotic prescription. Access to CRP and procalcitonin test results could have potentially decreased inappropriate antibiotic prescription in this study by 89.5% and 83.3%, respectively. High proportions of viral detection and antibiotic prescription were observed among a large inpatient cohort with LRTI. Increased access to point-of-care biomarker testing may improve antimicrobial prescription.

The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.

Many hospitals introduced procalcitonin (PCT) testing to help diagnose bacterial coinfection in individuals with COVID-19, and guide antibiotic decision-making during the COVID-19 pandemic in the UK. Evaluating cost-effectiveness of using PCT to guide antibiotic decisions in individuals hospitalized with COVID-19, as part of a wider research programme. Retrospective individual-level data on patients hospitalized with COVID-19 were collected from 11 NHS acute hospital Trusts and Health Boards from England and Wales, which varied in their use of baseline PCT testing during the first COVID-19 pandemic wave. A matched analysis (part of a wider analysis reported elsewhere) created groups of patients whose PCT was/was not tested at baseline. A model was created with combined decision tree/Markov phases, parameterized with quality-of-life/unit cost estimates from the literature, and used to estimate costs and quality-adjusted life years (QALYs). Cost-effectiveness was judged at a £20 000/QALY threshold. Uncertainty was characterized using bootstrapping. People who had baseline PCT testing had shorter general ward/ICU stays and spent less time on antibiotics, though with overlap between the groups' 95% CIs. Those with baseline PCT testing accrued more QALYs (8.76 versus 8.62) and lower costs (£9830 versus £10 700). The point estimate was baseline PCT testing being dominant over no baseline testing, though with uncertainty: the probability of cost-effectiveness was 0.579 with a 1 year horizon and 0.872 with a lifetime horizon. Using PCT to guide antibiotic therapy in individuals hospitalized with COVID-19 is more likely to be cost-effective than not, albeit with uncertainty.

Management of procalcitonin test overuse in an emergency department through a computer algorithm.

To show the procalcitonin (PCT) test demand from an emergency department (ED) over several years, to decrease PCT measurement via a computerized algorithm based on C-reactive protein (CRP) value, and to evaluate the subsequent economic savings. A cross-sectional study was performed from January 1, 2018, to May 31, 2019, to evaluate an intervention to avoid PCT measurement in the ED of Hospital Universitario San Juan in Alicante in Spain, when CRP values are low. A PCT result of at least 1.5 ng/mL was agreed upon with ED providers in our study as the value for clinical decision-making, with values less than 1.5 ng/mL considered negative. We retrospectively reviewed all PCT and CRP values for ED patients and calculated the diagnostic indicators for PCT at 4 different CRP cutoffs using the PCT quantification as the gold standard. From July 1, 2019, to April 30, 2021, the agreed-upon strategy was implemented, and we counted the PCT tests avoided and calculated the savings. PCT was not measured when CRP values were less than the selected CRP cutoff of 0.8 mg/dL, at which false-negative results were 1% and the 99th percentile of PCT was 1.5 ng/mL. In the postintervention period, 1091 PCT values were not measured and $11,553.69 was saved. An intervention to decrease PCT measurement in the ED designed by the clinical laboratory staff in consensus with requesting clinicians and based on CRP values decreased PCT testing and generated significant economic savings.

Antimicrobial prescribing in acute pancreatitis: Too much for too many?

BackgroundAcute pancreatitis (AP) is an inflammatory condition of the pancreas that varies widely in both clinical presentation and severity. Current international guidelines do not recommend the use of prophylactic antimicrobials in AP. AimTo review the compliance of antimicrobial prescribing in AP with international guidelines. MethodWe conducted a retrospective review of patients admitted with AP between 1st January 2021 and 31st December 2021, in Beaumont Hospital, Dublin, Ireland. For each case identified, the 2012 Revised Atlanta Criteria for AP were then applied on review of medical, laboratory and radiology records. ResultsThere were 98 patients, 52 % male (n = 51) with a median age of 53 years (range 18–88) who met the Revised Atlanta Criteria accounting for 1,032 hospital bed days inclusive of 82 critical care bed days. Gallstones were the most common aetiology; 48 % (n = 47). Antimicrobials were prescribed for 55 (56 %) patients with AP. Of those, only 38 % (n = 21) met the American Gastroenterological Association criteria for antimicrobials. The most common classes of antimicrobials prescribed were beta-lactams and carbapenems. Procalcitonin testing was conducted on just one patient (1 %). There were no cases of inpatient or 90-day mortality. ConclusionsOur findings are consistent with previously published reports of low mortality in mild acute AP and an excessive prescription of antimicrobials, highlighting this as an area for a targeted antimicrobial stewardship (AMS) intervention, including an increased use of procalcitonin as a biomarker.

To Compare Serum Procalcitonin And CRP As Markers Of Neonatal Sepsis

Objective: This study compares serum Procalcitonin (PCT) levels with CRP as predictive markers for neonatal sepsis. Method: It was a Quasi-experimental study performed in the neonatal intensive care unit (NICU) of Holy Family Hospital, Rawalpindi, for six months from July 2021 to January 2022 after the approval of the ethical board. The study included neonates admitted to the neonatal intensive care unit of Holy Family Hospital with a diagnosis of neonatal sepsis. Parents are permitted via written informed consent. A predesigned proforma was used to record clinical examinations, histories, and outcomes, which included hospital stay duration, complications, neonatal discharge, or mortality. Results: Seventy neonates meeting the study's inclusion criteria were enrolled. The average age in the study was 6.44 ± 5.24 days, with 40 (57.1%) males and 30 (42.9%) females. The CRP test demonstrated a sensitivity of 85.42%, specificity of 81.82%, positive predictive value (PPV) of 91.11%, negative predictive value (NPV) of 72.00%, and diagnostic accuracy of 84.29% in predicting neonatal sepsis. The PCT test displayed sensitivity, specificity, PPV, NPV, and diagnostic accuracy of 87.76%, 90.48%, 95.56%, 76.00%, and 88.57%, respectively. Conclusion: This study underscores Procalcitonin as a superior and early predictor compared to CRP in forecasting neonatal sepsis. Procalcitonin emerges as a particular marker for bacterial infections when contrasted with other inflammation indicators such as CRP, white blood cells, or lactate. Notably, Procalcitonin levels remain unaffected in viral or atypical bacterial infections. Keywords: Serum, Predictor, Neonatal, Sepsis.

Detection and Analysis of Commonly Used Infection Indicators in Patients with Acute Urticaria

Introduction: In this study, we investigated the correlation and clinical significance of peripheral blood leukocytes, neutrophils, C-reactive protein (CRP), and procalcitonin (PCT) in patients with acute urticaria. Methods: Complete blood count with differential, CRP, and PCT tests were conducted on patients with acute urticaria. A total of 614 patients with acute urticaria were divided into three groups: the first group consisted of patients with elevated leukocyte and neutrophil count, the second group consisted of patients with normal leukocyte and neutrophil count, and the third group consisted of patients with abnormal leukocyte and neutrophil count. A correlation analysis was conducted to investigate the levels of leukocytes, neutrophils, CRP, and PCT in the three groups. Results: The results of Kruskal-Wallis’ nonparametric test revealed statistically significant variations in leukocytes, neutrophils, CRP, and PCT among the three groups (p < 0.001). However, CRP and PCT showed no statistically significant differences between the second and third groups (p < 0.001, p = 0.0041, p = 0.0032). Additional multiple comparisons in Spearman correlation analysis indicated statistically significant differences (p = 0.55). Across all groups, there was a statistically significant difference in the correlation between CRP-PCT and leukocytes-neutrophils (p = 0.53). Conclusion: Leukocytes and neutrophils are sensitive to the impact of medications and stress on the body. Combining CRP and PCT, as well as routine blood test, may be a comprehensive assessment of infection presence and severity in patients, providing guidance for antibiotic treatment.

Diagnostic accuracy of procalcitonin in adult non-neutropenic cancer patients with suspected infection: a systematic review and meta-analysis

BackgroundProcalcitonin (PCT) has garnered attention as a potential diagnostic biomarker for infection in cancer patients. We performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of procalcitonin (PCT) and to compare it with C‐reactive protein (CRP) in adult non-neutropenic cancer patients with suspected infection.MethodsA systematic literature search was performed in MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials to identify all relevant diagnostic accuracy studies. Original articles reporting the diagnostic accuracy of PCT for infection detection in adult patients with solid or hematological malignancies were included. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, area under the hierarchical summary receiver operator characteristic (HSROC) curve, and corresponding 95% confidence interval (CI) were calculated.ResultsSeven studies were included in the meta-analysis. The pooled sensitivity and specificity of PCT were 60% (95% CI [45–74%]) and 78% (95% CI [69–86%]). The diagnostic odds ratio was estimated at 5.47 (95% CI [2.86–10.46]). Three studies compared the diagnostic accuracies of PCT and CRP. The pooled sensitivity and specificity values for PCT were 57% (95% CI [26–83%]) and 75% (95% CI [68–82%]), and those for CRP were 67% (95% CI [35–88%]) and 73% (95% CI [69–77%]). The pooled sensitivity and specificity of PCT and CRP did not differ significantly (p = 0.61 and p = 0.63). The diagnostic accuracy of PCT was similar to that of CRP as measured by the area under the HSROC curve (0.73, CI = 0.61–0.91 vs. 0.74, CI = 0.61–0.95, p = 0.93).ConclusionWhile elevated PCT levels can be indicative of potential infection, they should not be solely relied upon to exclude infection. We recommend not using the PCT test in isolation; Instead, it should be carefully interpreted in the context of clinical findings.

Correlation of Procalcitonin with Acid Fast Bacilli and Gene Xpert MTB/RIF as a Marker of Treatment Progress in Pulmonary Tuberculosis patients

There are several limitations in using AFB and GeneXpert to evaluate the treatment of TB patients, one of which is influenced by sputum quality. Therefore, an alternative method is needed to help evaluate the treatment of TB patients. This study aimed to analyze the correlation of the Procalcitonin test with AFB and GeneXpert for evaluating the treatment of TB patients and the performance of Procalcitonin as a marker of TB patient treatment progress. A prospective cohort study was conducted from May to September 2022 at the West Nusa Tenggara General Hospital, Indonesia. Sputum and blood samples were collected from 36 patients who were confirmed positive for TB by GeneXpert MTB/RIF examination, then examined for procalcitonin and AFB before being given treatment and after the intensive phase of treatment. Procalcitonin tested with VIDAS Biomerieux and VIDAS BRAHMS PCT kit. Procalcitonin did not correlate with AFB (p=0.064, r= 0.327) and GeneXpert before treatment (p=0.169, r=0.245), but correlated with AFB (p=0.013, r=0.427) and GeneXpert MTB/RIF (p=0.020, r=0.405) after the intensive phase of treatment. Procalcitonin test with a cut-off value of 0.07 detected negative AFB cases after treatment with a sensitivity of 28.6 and a specificity of 96.2%. The procalcitonin cut-off value of 0.07 also detected negative Xpert MTB/RIF after treatment with a sensitivity of 16.7% and a specificity of 100%. The performance of Procalcitonin for detecting negative smear and negative Xpert MTB/RIF after the intensive phase of treatment is classified as having high specificity, but its sensitivity is still low. Future studies are needed to evaluate the performance of Procalcitonin compared to bacterial cultures.

Accuracy of procalcitonin for diagnosing sepsis in adult patients admitted to the emergency department: a systematic review and meta-analysis.

Differentiating sepsis from non-infectious systemic inflammatory response syndrome (SIRS) is challenging. Biomarkers like procalcitonin (PCT) aid early risk assessment and guide antibiotic use. This study aims to ascertain PCT's accuracy as a sepsis biomarker among adult emergency department admissions. The PRISMA guidelines were followed to search for relevant articles in five electronic databases between April 14th and August 4th, 2023: PubMed, Cochrane Library, ProQuest, EMBASEs, and ScienceDirect. Studies had to be published in English to avoid directly translating scientific terms. Besides, the inclusion criteria were based on the diagnosis of sepsis in adult patients admitted to an emergency department. QUADAS-2 tool provided by the Review Manager version 5.4.1 was utilized to assess the risk of bias in included studies. STATA (v. 16) software was used to perform the meta-analysis. Ten of 2457 studies were included. We sampled 2980 adult sepsis patients for the under-investigated role of PCT in ED sepsis diagnosis. PCT emerged as the primary early diagnostic biomarker with high levels (29.3 ± 85.3ng/mL) in sepsis patients. Heterogeneity in outcomes, possibly due to bias in cohort and observational studies, was observed. PCT tests offer moderate accuracy in diagnosing sepsis and stand out for rapidly and precisely distinguishing between viral and bacterial inflammations.

Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world

BackgroundBacterial infections are not prevalent among patients hospitalized with COVID-19, while unnecessary prescription of antibiotics was commonly observed. This study aimed to determine the impact of procalcitonin testing on antibiotics prescription in the real-world setting.MethodsWe performed a territory-wide retrospective cohort study involving all laboratory-confirmed patients hospitalized in public hospitals in Hong Kong in 2020 with COVID-19. We determined the prevalence of bacterial co-infections (documented infections within 72 h of admission) and secondary bacterial infections (infections after 72 h of admission) and antibiotics consumption, and the correlation between procalcitonin testing and antibiotics prescription.ResultsThe cohort included 8666 patients, with mean age 45.3 ± 19.9 years, 48.5% male, and comorbidities in 26.9%. Among 2688 patients with bacterial cultures performed, 147 (5.5%) had bacterial co-infections, and 222 (8.3%) had secondary bacterial infections. Antibiotics were prescribed for 2773 (32.0%) patients during the hospital admission. Procalcitonin tests were performed for 2543 (29.3%) patients. More patients with procalcitonin testing received antibiotics (65.9% vs. 17.9%, p < 0.001). Procalcitonin testing was associated with 5-fold increased risk of antibiotics prescription after adjusting for confounding variables. At hospital level, procalcitonin testing correlated with antibiotics prescription. Patients with procalcitonin level < 0.5 ng/mL had a lower probability of antibiotics initiation and shorter duration of antibiotics therapy.ConclusionsProcalcitonin testing was not associated with lower prescription of antibiotics. Patients with low procalcitonin level had lower antibiotics exposure, supporting the use of procalcitonin to exclude bacterial infections aiding early stopping of antibiotics among patients hospitalized with COVID-19.

Microparticle-associated tissue factor activity correlates with the inflammatory response in septic disseminated intravascular coagulation patients.

Sepsis is often accompanied by the formation of disseminated intravascular coagulation (DIC). Microparticles can exert their procoagulant and proinflammatory properties in a variety of ways. The purpose of this study was to investigate the relationship between microparticle-associated tissue factor activity (TF+-MP activity) and the inflammatory response. Data from a total of 31 DIC patients with sepsis and 31 non-DIC patients with sepsis admitted to the ICU of the First Affiliated Hospital of Harbin Medical University from December 2017 to March 2019 were collected. Blood samples were collected and DIC scores were calculated on the day of enrollment. The hospital's clinical laboratory completed routine blood, procalcitonin, and C-reactive protein tests. TF+-MP activity was measured using a tissue factor-dependent FXa generation assay. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) levels were determined using ELISA kits. Compared with the non-DIC group, the DIC group had higher levels of leukocytes, neutrophils, procalcitonin, C-reactive protein, IL-1β, and TNF-α, and more severe inflammatory reactions. TF+-MP activity in the DIC group was higher than that in the non-DIC group. In sepsis patients, TF+-MP activity was strongly correlated with inflammatory response indices and DIC scores. TF+-MP activity may play a major role in promoting inflammatory response in septic DIC.